PDCD1 and hypophysitis: Results showed that individuals receiving combination therapy with anti-CTLA-4 and anti-PD- had a higher incidence of thyroid dysfunction and hypophysitis when compared to patients on CTLA-4 inhibitors or PD-1 inhibitors alone.